Becton Dickinson & CO BDX
We take great care to ensure that the data presented and summarized in this overview for BECTON DICKINSON & CO is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BDX
View all-
Vanguard Group Inc Valley Forge, PA26.2MShares$6.19 Billion0.13% of portfolio
-
Black Rock Inc. New York, NY22.8MShares$5.39 Billion0.13% of portfolio
-
State Street Corp Boston, MA13.5MShares$3.2 Billion0.15% of portfolio
-
Morgan Stanley New York, NY10.7MShares$2.53 Billion0.22% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10.1MShares$2.39 Billion0.31% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD7.5MShares$1.77 Billion1.14% of portfolio
-
Geode Capital Management, LLC Boston, MA6.03MShares$1.43 Billion0.14% of portfolio
-
Massachusetts Financial Services CO Boston, MA4.82MShares$1.14 Billion0.37% of portfolio
-
Wellington Management Group LLP Boston, MA4.75MShares$1.12 Billion0.21% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN4.75MShares$1.12 Billion0.33% of portfolio
Latest Institutional Activity in BDX
Top Purchases
Top Sells
About BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Insider Transactions at BDX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 15
2024
|
Roland Goette EVP and President EMEA |
SELL
Open market or private sale
|
Direct |
3,300
-8.16%
|
$778,800
$236.58 P/Share
|
May 13
2024
|
Roland Goette EVP and President EMEA |
SELL
Open market or private sale
|
Direct |
3,300
-6.46%
|
$782,100
$237.11 P/Share
|
Apr 30
2024
|
Michael David Garrison EVP & President Medical |
SELL
Open market or private sale
|
Direct |
1,715
-24.17%
|
$397,880
$232.81 P/Share
|
Apr 04
2024
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,921
-10.49%
|
-
|
Mar 14
2024
|
Thomas J Spoerel SVP,Controller&Chief Acct Off |
SELL
Open market or private sale
|
Direct |
282
-11.02%
|
$67,116
$238.29 P/Share
|
Mar 01
2024
|
Thomas J Spoerel SVP,Controller&Chief Acct Off |
SELL
Payment of exercise price or tax liability
|
Direct |
36
-1.39%
|
-
|
Mar 01
2024
|
Michael David Garrison EVP & President Medical |
SELL
Payment of exercise price or tax liability
|
Direct |
178
-2.45%
|
-
|
Mar 01
2024
|
Antoine C Ezell EVP, President NA & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
282
-2.94%
|
-
|
Jan 23
2024
|
Timothy M Ring Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+1.56%
|
-
|
Jan 23
2024
|
Bertram L Scott Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+2.49%
|
-
|
Jan 23
2024
|
Joanne Waldstreicher Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+40.49%
|
-
|
Jan 23
2024
|
Claire Fraser Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+3.81%
|
-
|
Jan 23
2024
|
Jeffrey William Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+13.91%
|
-
|
Jan 23
2024
|
Christopher Ian Montague Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+4.04%
|
-
|
Jan 23
2024
|
Catherine M Burzik Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+6.36%
|
-
|
Jan 23
2024
|
William M Brown Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+26.38%
|
-
|
Jan 23
2024
|
Carrie L Byington Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+23.97%
|
-
|
Jan 23
2024
|
R Andrew Eckert Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+9.97%
|
-
|
Jan 03
2024
|
David Shan EVP and Chief ISC Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
44
-0.77%
|
-
|
Dec 11
2023
|
Michael David Garrison EVP & President Medical |
SELL
Open market or private sale
|
Direct |
1,239
-14.55%
|
$287,448
$232.46 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 39.1K shares |
---|---|
Exercise of conversion of derivative security | 7.43K shares |
Grant, award, or other acquisition | 47 shares |
---|---|
Payment of exercise price or tax liability | 10.7K shares |
Open market or private sale | 17.6K shares |
Sale (or disposition) back to the issuer | 3.61K shares |